William J. Gradishar MD
The field of breast cancer has seen momentous progress over the last decade, particularly with novel agents for patients with HER2-positive disease.
, William J. Gradishar, MD, interim chief of hematology and oncology at Northwestern University’s Feinberg School of Medicine, discussed the latest developments in the HER2-positive setting, as well as biomarker development and the potential for immunotherapy in breast cancer.
OncLive: With the novel agents that have emerged in the HER2-positive setting, has an optimal sequence been determined?
HER2-positive cancer has been an area that has evolved over the last decade with the introduction of several new agents. They apply to patients both in early-stage and late-stage settings, as well as preoperatively. One of the challenges we have, particularly in patients with metastatic disease is how to optimally use these drugs, extend the time that patients have, and to really convey benefit to them.
... to read the full story